Eli Lilly and Company (LLY)
Lilly sues US agency over blocking of drug-rebate program
Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking the company's plan to change the way it offers drug discounts to hospitals.
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 515.88% and currently trading at $814.25. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years, Eli Lilly went from a $100 billion market capitalization to $740 billion today, which also makes it a potential stock split stock. However, as investors, we care about the stock price years down the line and what Eli Lilly will do in the next 3 to 5 years and beyond. That is why 24/7 Wall Street looks at projected revenue and net income to give you our best estimate of future stock prices from 2025 to 2030. Other “experts” look at past growth rates and assign future stock prices to those past numbers. However, we will walk you through our assumptions and give you the key drivers we see propelling Eli Lilly’s stock in the future. Recent Eli Lilly Stock Updates and News 11/14/2024 Eli Lilly’s weight-loss drug, tirzepatide, has shown promising results in preventing diabetes. After three years of weekly injections, nearly 99% of patients remained diabetes-free. This suggests that for every nine patients treated with tirzepatide, one new case of diabetes could be prevented. 11/12/2024 Eli Lilly’s CEO, Dave Ricks, has been named the recipient of the 2024 August M. Watanabe Life Sciences Champion of the Year Award by BioCrossroads. Under Ricks’ leadership, the company has invested billions of dollars in research and development to address critical health challenges, particularly in areas like oncology, obesity, immunology, and neurodegenerative diseases. 11/11/2024 Susan McGowan, a 58-year-old nurse from Scotland, tragically passed away after taking two doses of tirzepatide, a weight-loss drug manufactured by Eli Lilly. McGowan experienced multiple organ failure, pancreatitis, and septic shock a few days after taking the medication. This is believed to be the first such death in the U.K. officially linked to the medication. 11/8/2024 There is a strong bullish sentiment surrounding Eli Lilly, as seen by the increase in call option trading volume. This surge, particularly in the 820 and 830 strike calls expiring today, suggests that traders are anticipating a potential upside in the stock price. 11/7/2024 After a six-day losing streak, Eli Lilly’s stock is finally rebounding today. While the stock is still down 14% over the past month, it’s still outperforming the broader market, with a year-to-date gain of over 35% compared to the S&P 500’s 24%. 11/5/2024 Eli Lilly has announced that the company will present data from studies of Jaypirca (pirtobrutinib) at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego. The meeting and exposition will be held from December 7th through the 10th. 11/4/2024 Deutsche Bank analyst James Shin has lowered his price target slightly for Eli Lilly, reducing it from $1,025 to $1,015. However, he maintains a “Buy” rating on the stock. 10/31/2024 Eli Lilly released its quarterly earnings report, showcasing strong growth in Q3 and a total revenue rising 42% year-over-year. 10/29/2024 Eli Lilly has received approval to start selling its weight loss drug, Mounjaro, in Hong Kong as early as the end of this year. 10/28/2024 Eli Lilly will release its third-quarter results this Wednesday. Investors are keen to see how the company has performed, particularly regarding Mounjtaro and Zepbound. Analysts expect Eli Lilly to report $12.1 billion in sales and $1.45 in adjusted earnings per share for the quarter. 10/25/2024 Eli Lilly announced positive results from its Phase 3b study of Ebglyss, which focused on patients with moderate-to-severe atopic dermatitis. Patients had been previously treated with Dupixent with little success. However, the results of this latest Ebglyss study show that it was effective in improving skin and itch symptoms, particularly in challenging areas like the face and hands. 10/24/2024 Britain’s National Health Service (NHS) has announced that it will not cover Eli Lilly’s new Alzheimer’s drug, donanemab. Initially, the NHS was expected to approve the drug this week, but instead has decided that it’s too expensive for patients to use. Eli Lilly’s Recent Stock Success How did Eli Lilly’s stock price soar so much in the past few years? Let’s take a look at the numbers: Share Price Revenues* Net Income* 2016 $80.36 $21.22 $2.74 2017 $77.55 $19.94 ($0.21) 2018 $122.13 $21.49 $3.23 2019 $140.83 $22.32 $8.32 2020 $206.46 $24.54 $6.19 2021 $238.31 $28.32 $5.58 2022 329.07 $28.54 $6.25 2023 $745.91 $34.12 $5.24 *Revenue and Net Income in Billions Since 2016, Eli Lilly’s revenue grew by 60% but income grew by 91%. Typically you wouldn’t expect a company growing at its top line by 7% annually to see an 828% increase in share price, however, investor sentiment for the next line of drugs front ran the stock price. For example, in 2016 Eli Lilly was trading 13 times the trailing 12 months earnings and the market has increased its valuation each year and currently trades at a 125 times earnings multiple. This raises the valid question, is Eli Lilly overvalued or will future revenues make up for the expensive valuation? 3 Key Drivers of Eli Lilly Stock Innovated Drug Pipeline: The current drug pipeline is loaded with several very high-potential drugs in development. Mounjaro, Zepbound, and Jardiance in the cardiometabolic category, Taltz in immunology, and Verzenio in oncology are the future of Eli Lilly’s growth. While the aforementioned are the safer bets, the company has a handful of other drugs that could hold blockbuster potential. Strategic Acquisitions: The acquisition of Morphic, with its promising drug candidate MORF-057, is a testament to Lilly’s strategic vision. This drug, if successful in late-stage trials, could become a major success in the treatment of inflammatory bowel disease (IBD). Lilly’s focus on acquiring mid-sized companies (13 since 2020) with promising pipelines has bolstered its own research and development efforts, positioning it well for future growth. Operational Efficiency: With a sound balance sheet, Eli Lilly should continue to improve operational efficiency and manage costs to have net income growth rates above revenue growth. Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 26.50% higher than today’s price of $814.25. Of the 26 analysts covering Eli Lilly stock, the current rating is 1.67 or “Outperform” with 1-year price targets as high as $1,100 and as low as $540.00. 24/7 Wall Street sets its 1-year price target at $1,040. Taking a look at the sum of its parts, we see Eli Lilly’s vertices valued as follows: Endocrinology $735/ share Oncology $122/ Share Cardiovascular $4/ Share Neuroscience $16/ Share Immunology $38/ Share Others and Pipeline $110/ Share Cash $17/ Share Eli Lilly’s Share Price Estimates 2025-2030 Valuing Eli Lilly’s stock price for the coming years, we will take a look at expected revenue and net income and give our best estimate of the market value of the company by assigning a price-to-earnings multiple. Revenue Net Income EPS 2025 $52.8 $17.29 19.11 2026 $62.5 $22.49 25.03 2027 $70.87 $27.12 30.39 2028 $80.68 $32.2 25.97 2029 $87.99 $36.45 40.58 2030 $96.67 $41.12 46.29 *Revenue and net income reported in billions How Eli Lilly’s Next 5 Years Could Play Out We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong revenue growth of 18.37% to $52.80 billion and net income expansion to $17.29 billion, continuing the upward trajectory from previous years. For 2026, we anticipate a P/E ratio of 50 with an EPS of $25.03, leading to a price target of $1250.00. This reflects significant revenue growth of 18.37% to $62.50 billion and an increase in net income to $22.49 billion, driving higher earnings per share. Heading into 2027, we project the P/E ratio to remain at 50, with EPS increasing to $30.39. This results in a price target of $1520.00. Continued revenue growth of 13.39% to $70.87 billion and net income expansion to $27.12 billion justifies this substantial increase in stock price. With an EPS of $25.97 and a P/E ratio of 50 in 2028, we forecast the stock price to be $1300.00. A slight dip in EPS growth is expected, but sustained strong performance in net income to $32.20 billion and revenue growth of 13.84% to $80.68 billion keeps the stock highly valued. By 2029, we estimate Eli Lilly’s EPS to rise to $40.58, with the P/E ratio adjusting to 40. This gives us a price target of $1623.00. The continuous revenue growth of 9.06% to $87.99 billion and net income expansion to $36.45 billion supports this higher valuation. Eli Lilly Stocks Price Target for 2030 Price Target: $1850.00 Upside: 127.20% By 2030, we estimate Eli Lilly’s EPS to rise to $46.29, with the P/E ratio adjusting to 40. This gives us a price target of $1850.00. The continuous revenue growth of 9.86% to $96.67 billion and net income expansion to $41.12 billion supports this higher valuation. Year Price Target % Change From Current Price 2025 $1140.00 Upside of 10.01% 2026 $1250.00 Upside of 53.52% 2027 $1520.00 Upside of 86.67% 2028 $1300.00 Upside of 59.66% 2029 $1623.00 Upside of 99.32% 2030 $1850.00 Upside of 127.20% “The Next NVIDIA” Could Change Your Life If you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over. The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.” Click here to download your FREE copy. The post Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 appeared first on 24/7 Wall St..
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
On Wednesday, Eli Lilly And Co LLY released detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide.
2 Top Growth Stocks to Buy on the Dip
Their recent issues are nothing to fret over for investors focused on the long game.
Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections.
2 S&P 500 Dividend Stocks That Could Soar 30% or More, According to a Pair of Wall Street Analysts
If Wall Street's right, investors will get a lot more than just rising dividend payments from this pair.
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 531.19% and currently trading at $834.50. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years, Eli Lilly went from a $100 billion market capitalization to $740 billion today, which also makes it a potential stock split stock. However, as investors, we care about the stock price years down the line and what Eli Lilly will do in the next 3 to 5 years and beyond. That is why 24/7 Wall Street looks at projected revenue and net income to give you our best estimate of future stock prices from 2025 to 2030. Other “experts” look at past growth rates and assign future stock prices to those past numbers. However, we will walk you through our assumptions and give you the key drivers we see propelling Eli Lilly’s stock in the future. Recent Eli Lilly Stock Updates and News 11/12/2024 Eli Lilly’s CEO, Dave Ricks, has been named the recipient of the 2024 August M. Watanabe Life Sciences Champion of the Year Award by BioCrossroads. Under Ricks’ leadership, the company has invested billions of dollars in research and development to address critical health challenges, particularly in areas like oncology, obesity, immunology, and neurodegenerative diseases. 11/11/2024 Susan McGowan, a 58-year-old nurse from Scotland, tragically passed away after taking two doses of tirzepatide, a weight-loss drug manufactured by Eli Lilly. McGowan experienced multiple organ failure, pancreatitis, and septic shock a few days after taking the medication. This is believed to be the first such death in the U.K. officially linked to the medication. 11/8/2024 There is a strong bullish sentiment surrounding Eli Lilly, as seen by the increase in call option trading volume. This surge, particularly in the 820 and 830 strike calls expiring today, suggests that traders are anticipating a potential upside in the stock price. 11/7/2024 After a six-day losing streak, Eli Lilly’s stock is finally rebounding today. While the stock is still down 14% over the past month, it’s still outperforming the broader market, with a year-to-date gain of over 35% compared to the S&P 500’s 24%. 11/5/2024 Eli Lilly has announced that the company will present data from studies of Jaypirca (pirtobrutinib) at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego. The meeting and exposition will be held from December 7th through the 10th. 11/4/2024 Deutsche Bank analyst James Shin has lowered his price target slightly for Eli Lilly, reducing it from $1,025 to $1,015. However, he maintains a “Buy” rating on the stock. 10/31/2024 Eli Lilly released its quarterly earnings report, showcasing strong growth in Q3 and a total revenue rising 42% year-over-year. 10/29/2024 Eli Lilly has received approval to start selling its weight loss drug, Mounjaro, in Hong Kong as early as the end of this year. 10/28/2024 Eli Lilly will release its third-quarter results this Wednesday. Investors are keen to see how the company has performed, particularly regarding Mounjtaro and Zepbound. Analysts expect Eli Lilly to report $12.1 billion in sales and $1.45 in adjusted earnings per share for the quarter. 10/25/2024 Eli Lilly announced positive results from its Phase 3b study of Ebglyss, which focused on patients with moderate-to-severe atopic dermatitis. Patients had been previously treated with Dupixent with little success. However, the results of this latest Ebglyss study show that it was effective in improving skin and itch symptoms, particularly in challenging areas like the face and hands. 10/24/2024 Britain’s National Health Service (NHS) has announced that it will not cover Eli Lilly’s new Alzheimer’s drug, donanemab. Initially, the NHS was expected to approve the drug this week, but instead has decided that it’s too expensive for patients to use. 10/23/2024 A group of U.S. senators is investigating Eli Lilly and Pfizer’s new direct-to-consumer telehealth platforms, raising concerns about potential conflicts of interest for prescribers. LillyDirect and PfizerForAll offer virtual and in-person healthcare appointments, as well as convenient home delivery of prescription medications and other health products. Eli Lilly’s Recent Stock Success How did Eli Lilly’s stock price soar so much in the past few years? Let’s take a look at the numbers: Share Price Revenues* Net Income* 2016 $80.36 $21.22 $2.74 2017 $77.55 $19.94 ($0.21) 2018 $122.13 $21.49 $3.23 2019 $140.83 $22.32 $8.32 2020 $206.46 $24.54 $6.19 2021 $238.31 $28.32 $5.58 2022 329.07 $28.54 $6.25 2023 $745.91 $34.12 $5.24 *Revenue and Net Income in Billions Since 2016, Eli Lilly’s revenue grew by 60% but income grew by 91%. Typically you wouldn’t expect a company growing at its top line by 7% annually to see an 828% increase in share price, however, investor sentiment for the next line of drugs front ran the stock price. For example, in 2016 Eli Lilly was trading 13 times the trailing 12 months earnings and the market has increased its valuation each year and currently trades at a 125 times earnings multiple. This raises the valid question, is Eli Lilly overvalued or will future revenues make up for the expensive valuation? 3 Key Drivers of Eli Lilly Stock Innovated Drug Pipeline: The current drug pipeline is loaded with several very high-potential drugs in development. Mounjaro, Zepbound, and Jardiance in the cardiometabolic category, Taltz in immunology, and Verzenio in oncology are the future of Eli Lilly’s growth. While the aforementioned are the safer bets, the company has a handful of other drugs that could hold blockbuster potential. Strategic Acquisitions: The acquisition of Morphic, with its promising drug candidate MORF-057, is a testament to Lilly’s strategic vision. This drug, if successful in late-stage trials, could become a major success in the treatment of inflammatory bowel disease (IBD). Lilly’s focus on acquiring mid-sized companies (13 since 2020) with promising pipelines has bolstered its own research and development efforts, positioning it well for future growth. Operational Efficiency: With a sound balance sheet, Eli Lilly should continue to improve operational efficiency and manage costs to have net income growth rates above revenue growth. Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 23.43% higher than today’s price of $834.50. Of the 26 analysts covering Eli Lilly stock, the current rating is 1.67 or “Outperform” with 1-year price targets as high as $1,100 and as low as $540.00. 24/7 Wall Street sets its 1-year price target at $1,040. Taking a look at the sum of its parts, we see Eli Lilly’s vertices valued as follows: Endocrinology $735/ share Oncology $122/ Share Cardiovascular $4/ Share Neuroscience $16/ Share Immunology $38/ Share Others and Pipeline $110/ Share Cash $17/ Share Eli Lilly’s Share Price Estimates 2025-2030 Valuing Eli Lilly’s stock price for the coming years, we will take a look at expected revenue and net income and give our best estimate of the market value of the company by assigning a price-to-earnings multiple. Revenue Net Income EPS 2025 $52.8 $17.29 19.11 2026 $62.5 $22.49 25.03 2027 $70.87 $27.12 30.39 2028 $80.68 $32.2 25.97 2029 $87.99 $36.45 40.58 2030 $96.67 $41.12 46.29 *Revenue and net income reported in billions How Eli Lilly’s Next 5 Years Could Play Out We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of $19.11, resulting in a price target of $1140.00 This prediction is based on strong revenue growth of 18.37% to $52.80 billion and net income expansion to $17.29 billion, continuing the upward trajectory from previous years. For 2026, we anticipate a P/E ratio of 50 with an EPS of $25.03, leading to a price target of $1250.00. This reflects significant revenue growth of 18.37% to $62.50 billion and an increase in net income to $22.49 billion, driving higher earnings per share. Heading into 2027, we project the P/E ratio to remain at 50, with EPS increasing to $30.39. This results in a price target of $1520.00. Continued revenue growth of 13.39% to $70.87 billion and net income expansion to $27.12 billion justifies this substantial increase in stock price. With an EPS of $25.97 and a P/E ratio of 50 in 2028, we forecast the stock price to be $1300.00. A slight dip in EPS growth is expected, but sustained strong performance in net income to $32.20 billion and revenue growth of 13.84% to $80.68 billion keeps the stock highly valued. By 2029, we estimate Eli Lilly’s EPS to rise to $40.58, with the P/E ratio adjusting to 40. This gives us a price target of $1623.00. The continuous revenue growth of 9.06% to $87.99 billion and net income expansion to $36.45 billion supports this higher valuation. Eli Lilly Stocks Price Target for 2030 Price Target: $1850.00 Upside: 121.69% By 2030, we estimate Eli Lilly’s EPS to rise to $46.29, with the P/E ratio adjusting to 40. This gives us a price target of $1850.00. The continuous revenue growth of 9.86% to $96.67 billion and net income expansion to $41.12 billion supports this higher valuation. Year Price Target % Change From Current Price 2025 $1140.00 Upside of 36.61% 2026 $1250.00 Upside of 49.79% 2027 $1520.00 Upside of 82.14% 2028 $1300.00 Upside of 55.78% 2029 $1623.00 Upside of 94.49% 2030 $1850.00 Upside of 121.69% Smart Investors Are Quietly Loading Up on These “Dividend Legends” If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you. Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today. The post Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 appeared first on 24/7 Wall St..
Tradepulse Power Inflow Alert: Eli Lilly & Company Moves Up Over 13 Points After Signal
RISES OVER 1.6% AT IT'S HIGH FOR THE DAY AFTER EARLY DROP AND THE POWER INFLOW SIGNAL
Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?
One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in the third quarter.
1 Stubborn Cloud and 2 Silver Linings for Eli Lilly Stock
Conditions are getting a bit more challenging for the drugmaker.
Does This New Issue Threaten Eli Lilly and Novo Nordisk Shares?
The good times aren't over, but the peak of the party might be passing.
Eli Lilly Just Hit a Milestone That Disappointed. Here's Why You Should Still Buy the Stock.
The market's perception of the pharmaceutical company has undeniably shifted.
